AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. - 4. (Canceled)

5. (Currently amended) A therapeutic method for the treatment of spinal cord injury empirising-consisting of administering a subject in need thereof a therapeutic effective amount of at least one N-(2-aryl-propionyl)-sulfonamide of general formula (I):

in which

R2 is an aryl group,

R is a straight or branched C_1 - C_6 -alkyl, trifluoromethyl, cyclohexyl, o-tolyl, 3-pyridyl, 2-pyridylethyl, p-cyano-phenylmethyl, p-aminophenylmethyl, 3-cyano-l-propyl,

4-aminobutyl group, an alkoxyethylene CH_3 - $(CH_2)_{ni^-}$ ($OCH2CH2)_{mi^-}$ group in which n_i is zero or 1 and m_i is an integer of from 1 to 3, or a P_1P_2N - CH_2 - CH_2 - group in which P_1 and P_2 are independently H, C_1 - C_3 - alkyl, benzyloxy-carbonyl, a-, β - or α -pyridocarbonyl, carboxycarbonyl or carbalkoxycarbonyl, or P_1 and P_2 when joined to the N atom which they are linked to, form a phthalimido, piperidino, morpholino residue; R' is H or straight or branched C_1 - C_3 -alkyl.

- 6. (Previously presented). The therapeutic method according to claim 5 wherein R' is hydrogen.
- 7. (Currently amended) The therapeutic method according to claim 5, comprising administering the compounds of formula (Ia):

2 DRN/II

Application No. 10/588,454 Amendment dated November 22, 2010 After Final Office Action of May 21, 2010

(Ia)

wherein R represents one to three substituents, which are the same or different, selected from the group consisting of hydrogen, halogen atoms, C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy, hydroxy, C_1 - C_7 -acyloxy, cyano, nitro, amino, C_1 - C_3 -acylamino, halo C_1 - C_3 -alkyl, halo C_1 - C_3 -alkoxy, benzoyl, 4-(2-methyl-propyl)-phenyl, 3-phenoxy-phenyl, 2-[4-(1-oxo-2-isoindolinyl)phenyl], 5-benzoyl-thien-2-yl, 4-thienoyl-phenyl, and C_1 - C_3 -halogenoalkylsulphonyloxy.

- 8. (Currently amended) The therapeutic method according to claim 7 wherein R represents hydrogen, 4-isobutyl, 3-benzoyl, or 4-trifluoromethanesulphonyloxy.
- (Currently amended) The therapeutic method according to claim 7 wherein R represente represents 4-isobutyl - or 4-trifluoromethanesulphonyloxy.
- 10. (Currently amended) The therapeutic method according to claim 7 comprising administering at least one of the compounds of formula (II) and (HI)-(III)

(Currently amended) The therapeutic method according to claim 5, wherein the N-(2-aryl-propionyl)-sulfonamide is intravenously or intramuscularly administered.

3 DRN/II

Application No. 10/588,454 Amendment dated November 22, 2010 After Final Office Action of May 21, 2010

- 12. (Previously presented) The therapeutic method according to claim 11 wherein the N-(2-aryl-propionyl)-sulfonamide is administered as a bolus.
- (Currently amended) The therapeutic method according to claim 5, wherein the N-(2-aryl-propionyl)-sulfonamide is daily administered at least once in amounts ranging from 4+o1 to 1500 mg.
- 14. (Currently amended) A therapeutic method for blocking oligodendrocyte apoptosis, reducing tissue damage and promoting functional recovery following spinal cord injury eemprising consisting of administering a subject in need thereof a therapeutic effective amount of at least one of at least one N-(2-aryl-propionyl)-sulfonamide of general formula (I):

in which:

R2 is an aryl group,

R is a straight or branched C_1 - C_6 -alkyl, trifluoromethyl, cyclohexyl, o-tolyl, 3-pyridyl, 2-pyridylethyl, p-cyano-phenylmethyl, p-aminophenylmethyl, 3-cyano-l-propyl_xo<u>r</u> 4-aminobutyl group, an alkoxyethylene CH_3 - $(CH_2)_{ni}$ - $(OCH_2CH_2)_{mi}$ - group in which n_1 is zero

or 1 and m_i is an integer of from 1 to 3, or a P_1P_2N -CH₂-CH₂- group in which P_1 and P_2 are independently H, C_1 - C_3 - alkyl, benzyloxy-carbonyl, a-, β - or α -pyridocarbonyl, carboxycarbonyl or carbalkoxycarbonyl, or P_1 and P_2 when joined to the N atom which they are linked to, form a phthalimido, piperidino, or morpholino residue; and R' is H or straight or branched C_1 - C_3 -alkyl.

4